A recent enforcement memo from the U.S. Food and Drug Administration (FDA) signals that the agency will not block a new federal initiative allowing certain hemp-derived cannabidiol (CBD) products to be covered under a Medicare plan — a major change in how these products are treated at the federal level.
Under the memo, eligible Medicare patients may be able to receive up to $500 worth of hemp-derived products per year through this plan, effectively integrating compliant CBD into a federally subsidized healthcare benefit for the first time. The guidance clarifies that the FDA won’t interfere with this coverage effort, even though CBD products have long existed in a regulatory gray area under federal law.
This development opens up a new customer base for hemp CBD brands and retailers, particularly among older adults on Medicare. It also underscores the continuing distinction between federally legal hemp products (with low THC) and higher-THC cannabis products regulated at the state level.
Dabbin-Dad Newsroom
